These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20579252)

  • 41. Continued concern: human subject protection, the institutional review board, and continuing review.
    Hoffman S
    Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912
    [No Abstract]   [Full Text] [Related]  

  • 42. Making pragmatism practicable for the institutional review board.
    Robertson C
    Am J Bioeth; 2008 Apr; 8(4):49-51. PubMed ID: 18576258
    [No Abstract]   [Full Text] [Related]  

  • 43. Rethinking local Institutional Review Board (IRB) review at state health departments: implications for a consolidated, independent public health IRB.
    Perlman D
    J Law Med Ethics; 2012; 40(4):997-1007. PubMed ID: 23289701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of placebos in clinical trials: responsible research or unethical practice?
    Hoffman S
    Conn Law Rev; 2001; 33(2):449-501. PubMed ID: 15732201
    [No Abstract]   [Full Text] [Related]  

  • 45. The globalization of clinical trials: a growing challenge in protecting human subjects: executive summary (2001).
    Department of Health and Human Services, Office of the Inspector General, USA
    J Int Bioethique; 2003; 14(1-2):165-9. PubMed ID: 15035253
    [No Abstract]   [Full Text] [Related]  

  • 46. Children in clinical research: a conflict of moral values.
    Sharav VH
    Am J Bioeth; 2003; 3(1):W-IF 2. PubMed ID: 14560714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protecting clinical research and human participants: considerations for domestic and foreign clinical trials.
    Beach JE
    J Biolaw Bus; 2002; 5(3):41-5. PubMed ID: 12816117
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Financial conflicts of interest in human subjects research: proposals for a more effective regulatory scheme.
    Jordan KA
    Wash Lee Law Rev; 2003; 60(1):15-109. PubMed ID: 16273696
    [No Abstract]   [Full Text] [Related]  

  • 49. Institutional review boards and financial conflicts of interest.
    Maloney DM
    Hum Res Rep; 2002 Feb; 17(2):1-2. PubMed ID: 12374174
    [No Abstract]   [Full Text] [Related]  

  • 50. The role of institutional review boards in protecting human subjects: are we really ready to fix a broken system?
    Beh HG
    Law Psychol Rev; 2002; 26(1):1-47. PubMed ID: 16514756
    [No Abstract]   [Full Text] [Related]  

  • 51. Establishment of ethical oversight of human research in El Salvador: lessons learned.
    Caniza MA; Clara W; Maron G; Navarro-Marin JE; Rivera R; Howard SC; Camp J; Barfield RC
    Lancet Oncol; 2006 Dec; 7(12):1027-33. PubMed ID: 17138224
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protecting subjects, preserving trust, promoting progress II: principles and recommendations for oversight of an institution's financial interests in human subjects research.
    AAMC Task Force on Financial Conflicts of Interest in Clinical Research
    Acad Med; 2003 Feb; 78(2):237-45. PubMed ID: 12584107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmaceutical research: paradox, challenge or dilemma?
    Sheikh AL
    East Mediterr Health J; 2006; 12 Suppl 1():S42-9. PubMed ID: 17037688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protecting subjects, preserving trust, promoting progress I: policy and guidelines for the oversight of individual financial interests in human subjects research.
    AAMC Task Force on Financial Conflicts of Interest in Clinical Research
    Acad Med; 2003 Feb; 78(2):225-36. PubMed ID: 12584106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of the institutional review board in the oversight of the ethical aspects of human studies research.
    Cseko GC; Tremaine WJ
    Nutr Clin Pract; 2013 Apr; 28(2):177-81. PubMed ID: 23447409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time for new rules on human subjects research?
    Dresser R
    Hastings Cent Rep; 1998; 28(6):23-4. PubMed ID: 9868606
    [No Abstract]   [Full Text] [Related]  

  • 57. The investigational new drug application--who benefits?
    Freireich EJ
    Nat Clin Pract Oncol; 2006 Feb; 3(2):62-3. PubMed ID: 16462826
    [No Abstract]   [Full Text] [Related]  

  • 58. To expedite or not to expedite ...that is the question.
    Wicher CC; Michalek AM
    J Cancer Educ; 2008; 23(3):140-1. PubMed ID: 18709583
    [No Abstract]   [Full Text] [Related]  

  • 59. When informed consent is not required in studies.
    Maloney DM
    Hum Res Rep; 2006 Jun; 21(6):3. PubMed ID: 17111532
    [No Abstract]   [Full Text] [Related]  

  • 60. New guidelines for institutional review boards stress special role.
    Maloney DM
    Hum Res Rep; 2000 Dec; 15(12):1-2. PubMed ID: 11789516
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.